The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
ApexOnco Front Page
Recent articles
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
The FDA throws out the company’s second attempt at an accelerated approval.